A 16-year review of seroprevalence studies on measles and rubella
- PMID: 27340097
- DOI: 10.1016/j.vaccine.2016.06.002
A 16-year review of seroprevalence studies on measles and rubella
Abstract
The determination of the seroprevalence of vaccine-preventable diseases is critical in monitoring the efficacy of vaccination programmes and to assess the gaps in population immunity but requires extensive organisation and is time and resource intensive. The results of the studies are frequently reported in peer-reviewed scientific, government and non-government publications. A review of scientific literature was undertaken to advise the development of WHO guidelines for the assessment of measles and rubella seroprevalence. A search of the National Library of Medicine's PubMed online publications using key words of 'measles', 'rubella', combined with 'serosurvey', 'seroprevalence', 'immunity' and 'population immunity' was conducted. A total of 97 articles published between January 1998 and June 2014 were retrieved, 68 describing serosurveys for measles and 58 serosurveys for rubella, conducted in 37 and 36 different countries respectively. Only 13 (19%) and 8 (14%) respectively were UN classified "least developed countries". The study sample varied markedly and included combinations of male and female infants, children, adolescents and adults. The study sizes also varied with 28% and 33% of measles and rubella studies respectively, having greater than 2000 participants. Microtitre plate enzyme immunoassays were used in 52 (76%) measles studies and 40 (69%) rubella studies. A total of 39 (57%) measles and 44 (76%) rubella studies reported quantitative test results. Seroprevalence ranged from 60.8% to 95.9% for measles and 53.0% to 99.3% for rubella studies. The review highlighted that infants lost maternally-acquired immunity within 9months of birth and were unprotected until vaccination. Two groups at higher risk of infection were identified: young adults between the ages of 15 and 30years and immigrants.
Keywords: Measles; Rubella; Seroprevalence; Vaccination.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Similar articles
-
Measles and rubella serosurvey identifies rubella immunity gap in young adults of childbearing age in Zambia: The added value of nesting a serological survey within a post-campaign coverage evaluation survey.Vaccine. 2019 Apr 17;37(17):2387-2393. doi: 10.1016/j.vaccine.2019.02.037. Epub 2019 Mar 21. Vaccine. 2019. PMID: 30905529 Free PMC article.
-
Impact of a Measles and Rubella Vaccination Campaign on Seroprevalence in Southern Province, Zambia.Am J Trop Med Hyg. 2021 May 3;104(6):2229-2232. doi: 10.4269/ajtmh.20-1669. Am J Trop Med Hyg. 2021. PMID: 33939639 Free PMC article.
-
Evaluating the effect of measles and rubella mass vaccination campaigns on seroprevalence in India: a before-and-after cross-sectional household serosurvey in four districts, 2018-2020.Lancet Glob Health. 2022 Nov;10(11):e1655-e1664. doi: 10.1016/S2214-109X(22)00379-5. Lancet Glob Health. 2022. PMID: 36240831 Free PMC article.
-
A review of testing used in seroprevalence studies on measles and rubella.Vaccine. 2016 Jul 29;34(35):4119-4122. doi: 10.1016/j.vaccine.2016.06.006. Epub 2016 Jun 20. Vaccine. 2016. PMID: 27340096 Review.
-
Systematic Review of Measles and Rubella Serology Studies.Risk Anal. 2016 Jul;36(7):1459-86. doi: 10.1111/risa.12430. Epub 2015 Jun 16. Risk Anal. 2016. PMID: 26077609 Review.
Cited by
-
Serosurveillance for Measles and Rubella.Vaccines (Basel). 2024 Jul 22;12(7):816. doi: 10.3390/vaccines12070816. Vaccines (Basel). 2024. PMID: 39066453 Free PMC article. Review.
-
Correcting for Antibody Waning in Cumulative Incidence Estimation From Sequential Serosurveys.Am J Epidemiol. 2024 May 7;193(5):777-786. doi: 10.1093/aje/kwad226. Am J Epidemiol. 2024. PMID: 38012125 Free PMC article.
-
Clinical characteristics of adult inpatients with Measles in Beijing from 2010 to 2021: a retrospective analysis.BMC Infect Dis. 2023 May 9;23(1):312. doi: 10.1186/s12879-023-08256-2. BMC Infect Dis. 2023. PMID: 37161385 Free PMC article.
-
Design of a chimaeric antigen and its use in the detection of IgG antibodies against rubella virus.Virol J. 2022 Feb 23;19(1):33. doi: 10.1186/s12985-022-01760-y. Virol J. 2022. PMID: 35197095 Free PMC article.
-
Rubella Eradication: Not Yet Accomplished, but Entirely Feasible.J Infect Dis. 2021 Sep 30;224(12 Suppl 2):S360-S366. doi: 10.1093/infdis/jiaa530. J Infect Dis. 2021. PMID: 34590132 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical